{
    "nctId": "NCT02964715",
    "officialTitle": "The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes",
    "inclusionCriteria": "* biopsy proven NASH\n* Type 2 DM\n* HbA1c :\\>6.5%\n* BMI \\< 45kg/m2\n* Any anti-diabetic agent except SGLT2 inhibitors, TZDs(thiazolidinediones), DPP4(Dipeptidyl peptidase4) inhibitors and GLP1 RAs(Glucagon-like Peptide 1-Receptor Agonists)\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* eGFR \\<45 ml/min\n* structural and functional urogenital abnormalities, that predispose for urogenital infections\n* Investigational product use in the last 6 months\n* SGLT2 inhibitor, TZD, DPP4 inhibitor and GLP1 RA use within the past 6 months\n* DKA(Diabetic Ketoacidosis) or HHS(Hyperosmoloar Hyperglycaemic Syndrome) within the last 6 months\n* Pregnancy\n* Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).\n* Liver cirrhosis\n* Type 1 diabetes\n* Severe uncorrected insulin insufficiency\n* Significant alcohol intake\n* HIV infection\n* Use of Traditional Chinese Medication or alternative therapies\n* Coexisting causes of chronic liver disease - chronic viral hepatitis(B \\& C), autoimmune liver disease, hemochromatosis, Wilson's etc.\n* Use of medications associated with steatosis eg. Methotrexate, anticonvulsants, antiretroviral therapy etc.\n* h/o stroke\n* Steroid therapy\n* Endogenous Cushing's\n* Familial hypertriglyceridemia"
}